Study on the efficacy of Balenine in preventing cognitive decline

An exploratory, placebo-controlled, randomized, double-blind comparative study on the efficacy of Balenine in preventing cognitive decline

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs021250025

Enrollment

Registered

2025-10-14

Start date

2025-10-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dementia

Interventions

Take one capsule containing Balenine (500 mg) or placebo once a day after a meal (for approximately 12 weeks)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Dementia and regular medical visits possible. (2) Mini-mental state examination (MMSE) score of 21 or more. (3) Age 18 or older at the time of consent. (4) The subject or a legal representative must give written consent to participate in the study.

Exclusion criteria

Exclusion criteria: (1) Patients who do not meet the eligibility criteria (2) Patients who are judged by the principal investigator or co-investigator to be inappropriate for participation in this study

Design outcomes

Primary

Measure	Time frame
Change in MMSE	—

Secondary

Measure	Time frame
safety MMSE responder rate MoCA-J responder rate and change Cogstate Brief Battery Patient's global impression	—

Countries

Japan, nome

Contacts

Public ContactTetsuro Yamashita

Iwate University

yamashit@iwate-u.ac.jp+81-19-621-6157

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026